150 related articles for article (PubMed ID: 16163541)
1. Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients.
Fabi A; Ferretti G; Papaldo P; Salesi N; Ciccarese M; Lorusso V; Carlini P; Carpino A; Mottolese M; Cianciulli AM; Giannarelli D; Sperduti I; Felici A; Cognetti F
Cancer Chemother Pharmacol; 2006 May; 57(5):615-23. PubMed ID: 16163541
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer.
Rivera E; Valero V; Arun B; Royce M; Adinin R; Hoelzer K; Walters R; Wade JL; Pusztai L; Hortobagyi GN
J Clin Oncol; 2003 Sep; 21(17):3249-54. PubMed ID: 12947059
[TBL] [Abstract][Full Text] [Related]
3. Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience.
Martin-Romano P; Baraibar I; Espinós J; Legaspi J; López-Picazo JM; Aramendía JM; Fernández OA; Santisteban M
Breast J; 2018 Jul; 24(4):473-479. PubMed ID: 29286192
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience.
Passardi A; Massa I; Zoli W; Gianni L; Milandri C; Zumaglini F; Nanni O; Maltoni R; Frassineti GL; Amadori D
BMC Cancer; 2006 Mar; 6():76. PubMed ID: 16551351
[TBL] [Abstract][Full Text] [Related]
5. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
[TBL] [Abstract][Full Text] [Related]
6. The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial.
Al-Batran SE; Bischoff J; von Minckwitz G; Atmaca A; Kleeberg U; Meuthen I; Morack G; Lerbs W; Hecker D; Sehouli J; Knuth A; Jager E
Br J Cancer; 2006 Jun; 94(11):1615-20. PubMed ID: 16685267
[TBL] [Abstract][Full Text] [Related]
7. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of pegylated liposomal doxorubicin (Caelyx) plus Gemcitabine in chemotherapeutically pretreated patients with advanced breast cancer.
Ulrich-Pur H; Kornek GV; Haider K; Kwasny W; Payrits T; Dworan N; Vormittag L; Depisch D; Lang F; Scheithauer W
Acta Oncol; 2007; 46(2):208-13. PubMed ID: 17453371
[TBL] [Abstract][Full Text] [Related]
9. Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study.
Rau KM; Lin YC; Chen YY; Chen JS; Lee KD; Wang CH; Chang HK
BMC Cancer; 2015 May; 15():423. PubMed ID: 25994543
[TBL] [Abstract][Full Text] [Related]
10. Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials.
Al-Batran SE; Güntner M; Pauligk C; Scholz M; Chen R; Beiss B; Stopatschinskaja S; Lerbs W; Harbeck N; Jäger E
Br J Cancer; 2010 Nov; 103(10):1518-23. PubMed ID: 20978502
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II study of gemcitabine with pegylated liposomal doxorubicin as first-line therapy in Asian women with metastatic breast cancer.
Wong ZW; Ang PC; Chowbay B; Wong NS; See HT; Khoo KS
Breast; 2008 Oct; 17(5):517-22. PubMed ID: 18502128
[TBL] [Abstract][Full Text] [Related]
12. Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial.
Del Barco S; Colomer R; Calvo L; Tusquets I; Adrover E; Sánchez P; Rifà J; De la Haba J; Virizuela JA
Breast Cancer Res Treat; 2009 Jul; 116(2):351-8. PubMed ID: 18941891
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study.
Schmid P; Heilmann V; Schulz CO; Dieing A; Lehenbauer-Dehm S; Jehn C; Sezer O; Possinger K; Flath B
J Cancer Res Clin Oncol; 2005 Sep; 131(9):568-74. PubMed ID: 16044345
[TBL] [Abstract][Full Text] [Related]
14. Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study.
Adamo V; Lorusso V; Rossello R; Adamo B; Ferraro G; Lorusso D; Condemi G; Priolo D; Di Lullo L; Paglia A; Pisconti S; Scambia G; Ferrandina G
Br J Cancer; 2008 Jun; 98(12):1916-21. PubMed ID: 18493232
[TBL] [Abstract][Full Text] [Related]
15. Pegylated liposomal doxorubicin (Duomeisu
Jiang H; Li H; Song G; Di L; Shao B; Yan Y; Liu X; Chen Y; Zhang R; Ran R; Liu Y; Gui X; Wang N; Wang H
Breast Cancer Res Treat; 2023 May; 199(1):67-79. PubMed ID: 36877215
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of pegylated liposomal doxorubicin in combination with gemcitabine in metastatic breast cancer patients.
Jacquin JP; Chargari C; Thorin J; Mille D; Mélis A; Orfeuvre H; Clavreul G; Chaigneau L; Nourissat A; Dumanoir C; Savary J; Merrouche Y; Magné N
Am J Clin Oncol; 2012 Feb; 35(1):18-21. PubMed ID: 21278560
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study.
Harbeck N; Saupe S; Jäger E; Schmidt M; Kreienberg R; Müller L; Otremba BJ; Waldenmaier D; Dorn J; Warm M; Scholz M; Untch M; de Wit M; Barinoff J; Lück HJ; Harter P; Augustin D; Harnett P; Beckmann MW; Al-Batran SE;
Breast Cancer Res Treat; 2017 Jan; 161(1):63-72. PubMed ID: 27798749
[TBL] [Abstract][Full Text] [Related]
18. Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer.
Tas F; Guney N; Derin D; Camlica H; Aydiner A; Topuz E
Invest New Drugs; 2008 Aug; 26(4):363-8. PubMed ID: 18165864
[TBL] [Abstract][Full Text] [Related]
19. Low dose gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapsed breast cancer after taxane-anthracycline-containing regimens.
Sánchez-Escribano Morcuende R; Alés-Martínez JE; Aramburo González PM
Clin Transl Oncol; 2007 Jul; 9(7):459-64. PubMed ID: 17652060
[TBL] [Abstract][Full Text] [Related]
20. Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial.
Murialdo R; Bertolotti F; Pastorino G; Mencoboni M; Bergaglio M; Folco U; Cinzia N; Vaira F; Simoni C; Canobbio L; Parodi M; Brema F; Ballestrero A
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1009-16. PubMed ID: 21327683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
